Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)’s share price shot up 6.9% during trading on Thursday . The company traded as high as $23.02 and last traded at $23.00, with a volume of 120,252 shares traded. The stock had previously closed at $21.52.

A number of research firms recently commented on ENTA. Vetr downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 price target for the company. in a research note on Monday, April 25th. JMP Securities downgraded Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 28th. Finally, Zacks Investment Research downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $28.58.

The company has a market capitalization of $420.09 million and a P/E ratio of 13.03. The company’s 50-day moving average price is $22.95 and its 200 day moving average price is $26.45.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.10 by $0.19. The company had revenue of $13 million for the quarter, compared to analysts’ expectations of $16.80 million. During the same period in the previous year, the company earned $1.49 EPS. The company’s quarterly revenue was down 77.4% compared to the same quarter last year. Analysts predict that Enanta Pharmaceuticals Inc. will post $1.00 EPS for the current year.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. Matarin Capital Management LLC purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth $4,644,000. Schroder Investment Management Group raised its position in Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock worth $14,506,000 after buying an additional 210,303 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in Enanta Pharmaceuticals by 114.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 32,851 shares of the company’s stock worth $1,085,000 after buying an additional 17,551 shares in the last quarter. GSA Capital Partners LLP raised its position in Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock worth $2,652,000 after buying an additional 24,670 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in Enanta Pharmaceuticals by 8.0% in the fourth quarter. New York State Common Retirement Fund now owns 133,569 shares of the company’s stock worth $4,410,000 after buying an additional 9,871 shares in the last quarter.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.